The SA Journal Diabetes & Vascular Disease Vol 15 No 2 (November 2018)

13 / 52

SA JOURNAL OF DIABETES & VASCULAR DISEASE RESEARCH ARTICLE
VOLUME 15 NUMBER 2 • NOVEMBER 2018 51
15. Daleva M, Piperova-Dalbokova D, Hadjiolova I, et al. Changes in the excretion
of corticosteroids and catecholamines in tractor-drivers. Int Arch Occup Environ
Health 1982; 49: 345–352.
16. Sato S, Taoda K, Kawamura M, et al. Heart rate variability during long truck
driving work. J Hum Ergol (Tokyo) 2001; 30: 235–240.
17. (2012).World’s fastest growing cities and urban areas from
2006–2020. Accessed Feb 13, 2015.
18. Lagos metropolitan area transport. Lagos: Bureau of Statistics. Digest of Statistics,
2010.
19. Amoran OE, Salako EE, Jeminusi O. Screening for common occupational health
disease among long distance professional drivers in Sagamu, Ogun state, Nigeria.
Int J Prev Med 2014; 5(4): 516–521.
20. Tobin EA, Ofili AN, Asogun DA, et al. Prevalence of hypertension and associated
factors among inter-city drivers in an urban city in South- South Nigeria. Int J Res
Med 2013; 2(3): 5–12.
21. Erhiano EE, Igbokwe VU, El-Khashab MM, Okolo RU, Awosan KJ. Prevalence of
hypertension among commercial bus drivers in Sokoto, Sokoto state, Nigeria. Int
J Med Med Sci 2015; 2(3): 34–39.
22. Ogah OS, Okpechi I, Chukwunoye II. Blood Pressure, prevalence of hypertension
and hypertension related complications in Nigerian Africans: A review. World J
Cardiovascular Dis 2012; 4(12): 327–340.
23.
24. Rolland-Cachera MF, Sempe M, Guilloud-Bataille M, Patois E, et al. Adiposity
Indices in children. Am J Clin Nutr 1982; 36: 178–184.
25. The WHO STEPwise approach to non-communicable disease risk factor
surveillance (STEPS). www.who.int/chp/steps. Accessed April 12, 2015.
26. Ozoh OB, Okubadejo NU, Dania MG. High risk of obstructive sleep apnea
and excessive daytime sleepiness among commercial intra-city drivers in Lagos
metropolis. Niger Med J 2013; 54(4): 224–229.
27.
28. American Diabetic Association diagnostic criteria.
basic/diagnosis; 2014. Accessed June 19, 2015.
29. National Cholesterol Education Program: ATP III Guidelines 2001. www.nhlbi.nih.
gov/files/docs/guidelines/atp3xsum.pdf. Accessed on May 20, 2015.
30. Castelli WP, Anderson K, Wilson PW, Levy D. Lipis and the risk of coronary heart
disease. The Framingham Study. Ann Epidemiol 1992; 2(1–2): 23–28.
31. www.who.int/steps/resources/GPAQ_Analysis_Guide.pdf. Accessed May 20, 2015.
32. Adeloye D, Basquill C, Aderemi AV, et al . An estimate of the prevalence of
hypertension in Nigeria: a systematic review and meta-analysis. J Hypertens 2015;
33(2): 230–242.
33. Murthy GVS, Fox S, Sivasubramanian S, Gilbert CE, Mahdi AM. Prevalence and
risk factors of hypertension and association with ethnicity in Nigeria: results from
a national survey. Cardiovas J Afr 2013; 24(9): 344–350.
34. Ekwunife OI, Udeogaranya P, Nwatu I. Prevalence, awareness, treatment and
control of hypertension in a Nigerian population. Health 2010; 2: 731–735.
35. Iseuzo S, Sabir AA, Ohwovoriole AE, Fasanmade OA. Prevalence, associated
factors and relationship between prehypertension and hypertension: a study
of two ethnic African populations in northern Nigeria. J Hum Hypertens 2010;
25(4): 224–230.
36. Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, et al. In: Guariguata
L, Nolan T, Beagley J, Linnenkamp U, Jacqmain O (eds). International Diabetes
Federation Atlas. Basel, Switzerland: International Diabetes Federation, 2013.
37. Ogbera OA, Ekpebegh C. Diabetes Mellitus in Nigeria: The past, present and
future. World J Diabetes 2014; 5(6): 905–911.
38. Odenigbo CV, Oguejiofor OC, Odenigbo UM,et al. Prevalence of dyslipidaemia in
apparently healthy professionals in Asaba, South- South Nigeria. Nig J Clin Pract
2008; 11: 330–335.
39. Ono T, Guthold R, Strong K. WHO Global Comparable Estimates. Global Infobase
data for saving lives 2005–2012. infobase/index.aspx.
Accessed February 23, 2015.
40. Okafor CI, Gezawa ID, Sabir AA, Raimi TH, Enang O. Obesity, overweight and
underweight among urban Nigerians. Nig J Clin Pract 2014; 17: 743–749.
41. Saberi HR, Moravveji AR, Frakhanan E, Kashani, et al. Prevalence of metabolic
syndrome in bus and truck drivers in Kashan, Iran. Diabetol Metabolic Syndrome
2011; 3(1): 8.
42. Hirata RP, Malosa Sampio LM, Leitao Filho FS, et al. General characteristics and
risk Factors of Cardiovascular Disease among Interstate Bus Drivers. Sci W J 2012;
Article ID 216702: 1–8.
43. Barbosa PJB, Leaas I, Filho NA, Magalhaes LB, Araujo J. Criteria for central obesity
in a Brazilian population: impact on metabolic syndrome. Arq Bras Cardiol 2006;
87(4): 1–8.
44. Shabnam AA, Homa K, Reza MM, Bagher L, et al. Cut-off points for
waist circumference and body mass index for detecting diabetes mellitus,
hypercholestrolaemia and hypertension according to the national non-
communicable risk factor surveillance in Iran. Arch Med Sci 2012; 8(4): 614–
621.
45. Lakshman A, Manikath N, Rahim A, Anilakumari VP. Prevalence and risk factors
for hypertension among male occupational bus drivers in North Kerla, South
India: A cross-sectional study. ISRN Prev Med 2914; Article 19 318532; 1–9.
46. Zhu S, Kim J, Ma X, Shih A, et al. Body mass index and risk of serious upper
body injuries following motor vehicle crashes: concordance of real-world and
computer-simulated observations. PLos Med 2010; 7(3): e 1000250.
47. World Health Organization. Cardiovascular diseases. Factsheet No 317, 2015.
www.who.int/mediacentre/factsheets/fs317/en/index. Accessed February 22,
2015.
48. Adejugbagbe AM, Fatiregun AA, Rukewe A, Alonge T. Epidemiology of road
traffic crashes among long distance drivers in Ibadan. Afr Health Sci 2015; 15(2):
483–488.
49. Bello S, Ndifon OO, Mpama OO, Odowole OO. Pattern of alcohol use among
drivers of commercial vehicles in Calabar, Nigeria. E Afr Med J 2011; 88(33): 3–6.
50. Chukwuonye II, Chuku A, Onyeonoro UU, Madukwe OO, et al. A rural and urban
cross-sectional study on alcohol consumption among adult Nigerians in Abia
state. Int J Med Biomed Res 2013; 2( 3): 179–185.
51. World Health Organization. Management of substance abuse. Country profiles,
2014. www.who.int/substance_abuse/publications/global_alcohol_report/profile/
nga.pdf?ua=1. Accessed August 28, 2015.
52. Mancia G, Parati G, Borghi C, Ghironzi G,et al. Smooth investigators. Hypertension
prevalence, awareness, control and association with metabolic abnormalities in
San Maniano population the SMOOTH study. J Hypertens 2006; 24: 837–843.
53. Mancia G,Bombelli M, Corrao G, Facchetti R, Madotto F, et al. Metabolic
syndrome in the PAMELA study: daily life blood pressure, cardiac damage, and
prognosis. Hypertension 2007; 49: 40–47.
54. Mancia G, Grassi G. Systolic and diastolic blood pressure control in anti-
hypertensive drug trials. J Hypertens 2007; 20: 1461–1464.
55. Showande SJ, George OA, Adekunle OO. Gender-related differences in the
prevalence and correlates of modifiable cardiovascular disease risk factors among
seemingly healthy adult Nigerians – a cross-sectional study. Br J Med Med Res
2014: 4(25): 4325–4340.
56. Mahmoud US, Kolawole WW, Bashir OY, Maruf G, Omolara VJ, Akeem G.
Modifiable cardiovascular risk factors among apparently healthy adult Nigerian
population – a cross-sectional study. BMC Res Notes 2010; 3(11): 1–7.
57. Oladapo OO, Falase AO, Salako L, Sodiq O, Shoyinka K, Adedapo K. A prevalence
of cardiometabolic risk factors among a rural Yoruba southwestern Nigerian
population: a population-based survey. Cardiovasc J Afr 2010; 21(1): 26–31.